Pyxis Oncology (NASDAQ:PYXS) Rating Lowered to Market Perform at William Blair

William Blair lowered shares of Pyxis Oncology (NASDAQ:PYXS - Free Report) from an outperform rating to a market perform rating in a research note issued to investors on Thursday morning, MarketBeat Ratings reports.

Several other research firms have also issued reports on PYXS. Royal Bank of Canada restated an "outperform" rating and set a $7.00 target price on shares of Pyxis Oncology in a research report on Thursday, September 19th. HC Wainwright reiterated a "buy" rating and issued a $7.00 target price on shares of Pyxis Oncology in a report on Friday, August 16th. Stephens assumed coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They set an "overweight" rating and a $13.00 price target on the stock. Finally, Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They issued a "buy" rating and a $10.00 price objective for the company. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $10.00.

Pyxis Oncology Trading Down 44.2 %

Shares of NASDAQ:PYXS traded down $1.69 during midday trading on Thursday, hitting $2.13. The company had a trading volume of 14,504,299 shares, compared to its average volume of 718,323. Pyxis Oncology has a 12 month low of $1.35 and a 12 month high of $6.85. The firm has a fifty day simple moving average of $3.71 and a 200 day simple moving average of $3.64. The stock has a market cap of $126.67 million, a price-to-earnings ratio of -1.96 and a beta of 1.27.

Institutional Trading of Pyxis Oncology

Institutional investors have recently modified their holdings of the company. Ikarian Capital LLC acquired a new position in Pyxis Oncology during the 1st quarter worth approximately $7,082,000. Blue Owl Capital Holdings LP bought a new stake in shares of Pyxis Oncology in the second quarter worth $3,462,000. Millennium Management LLC boosted its holdings in Pyxis Oncology by 125.3% during the second quarter. Millennium Management LLC now owns 1,336,908 shares of the company's stock worth $4,425,000 after purchasing an additional 743,499 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Pyxis Oncology in the third quarter valued at $1,405,000. Finally, State Street Corp increased its stake in Pyxis Oncology by 28.0% in the 3rd quarter. State Street Corp now owns 951,251 shares of the company's stock valued at $3,491,000 after buying an additional 208,344 shares during the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.